AU2001271365A1 - Cyr61 as a target for treatment and diagnosis of breast cancer - Google Patents

Cyr61 as a target for treatment and diagnosis of breast cancer

Info

Publication number
AU2001271365A1
AU2001271365A1 AU2001271365A AU7136501A AU2001271365A1 AU 2001271365 A1 AU2001271365 A1 AU 2001271365A1 AU 2001271365 A AU2001271365 A AU 2001271365A AU 7136501 A AU7136501 A AU 7136501A AU 2001271365 A1 AU2001271365 A1 AU 2001271365A1
Authority
AU
Australia
Prior art keywords
cyr61
diagnosis
target
treatment
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271365A
Inventor
Deepak Sampath
Richard Winneker
Zhiming Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001271365A1 publication Critical patent/AU2001271365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2001271365A 2000-06-21 2001-06-21 Cyr61 as a target for treatment and diagnosis of breast cancer Abandoned AU2001271365A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21318200P 2000-06-21 2000-06-21
US60213182 2000-06-21
US29151001P 2001-05-16 2001-05-16
US60291510 2001-05-16
PCT/US2001/019823 WO2001098359A2 (en) 2000-06-21 2001-06-21 Cyr61 as a target for treatment and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
AU2001271365A1 true AU2001271365A1 (en) 2002-01-02

Family

ID=26907838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271365A Abandoned AU2001271365A1 (en) 2000-06-21 2001-06-21 Cyr61 as a target for treatment and diagnosis of breast cancer

Country Status (2)

Country Link
AU (1) AU2001271365A1 (en)
WO (1) WO2001098359A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230732A1 (en) * 2002-03-25 2003-10-13 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Use of cyr61 for the diagnosis of acute renal failure
EP2233926A3 (en) * 2003-04-01 2011-01-12 The Johns Hopkins University Breast Endothelial Cell Expression Patterns
JP2004315480A (en) * 2003-04-21 2004-11-11 Yoshiyuki Kakehi Medicinal composition for prostate disease treatment
DK1641810T4 (en) 2003-06-24 2017-07-03 Genomic Health Inc Predicting the likelihood of cancer recurrence
JP5006802B2 (en) 2005-02-18 2012-08-22 チルドレンズ メディカル センター コーポレイション Cyr61 as a biomarker for cancer diagnosis and prognosis derived from epithelium
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
WO2011066783A1 (en) * 2009-12-04 2011-06-09 上海市免疫学研究所 Anti-cyr61 protein monoclonal antibodies and uses thereof
DE102010010288A1 (en) 2010-03-04 2011-09-08 Wolfgang Poller Medicament, useful to prevent or treat e.g. ulcerative colitis, comprises polypeptide sequences of cysteine-rich protein 61 (CCN1) and/or cyclic arginine-glycine-aspartic acid peptide, or nucleic acid encoding polypeptide sequence of CCN1
WO2011107590A1 (en) 2010-03-04 2011-09-09 Wolfgang Poller Cnn1 (cyr61) for prevention and therapy of inflammatory disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4307552B2 (en) * 1996-03-15 2009-08-05 ミューニン コーポレイション Extracellular matrix signaling molecules
HUP0302052A3 (en) * 1999-07-14 2005-12-28 Novo Nordisk Healthcare Ag Use of fviia or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis

Also Published As

Publication number Publication date
WO2001098359A3 (en) 2002-06-06
WO2001098359A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU1807401A (en) Compositions and methods for therapy and diagnosis of breast cancer
AU2001268259A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001269766A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU4185100A (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
PL365244A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2002218770A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU3391200A (en) Compositions and methods for breast cancer therapy and diagnosis
AU2001280982A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001252945A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
AU2000274383A1 (en) Preparation for treating diseases of bone tissues
AU2002303219A1 (en) Compositions and methods for the therapy and diagnosis of cancer
AU2002246519A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2002348297A1 (en) Proteonomic methods for diagnosis and monitoring of breast cancer
AU2001271365A1 (en) Cyr61 as a target for treatment and diagnosis of breast cancer
AU2001243349A1 (en) Methods for the diagnosis and treatment of breast cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002313726A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2001290518A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU3177500A (en) Proteins for diagnosis and treatment of breast cancer
AU5638400A (en) Compositions and methods for the therapy and diagnosis of breast cancer
PL366066A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer